CD9 and prostate cancer: Therefore, to characterise further the role played by CD9 in prostate cancer, we stably transfected and overexpressed wild-type CD9 in PC-3 cells and its derivatives (all originally obtained upon injection in nude mice), namely PC-3M (a liver metastasis obtained upon PC-3 intraspleenic injection), PC-3M-Pro4 (a highly aggressive cancer cell line selected upon sequential orthotopic PC-3M injections) and PC-3M-LN4 (a very aggressive lymph node metastatic cell line selected upon sequential orthotopic PC-3M injection).